Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

464.93 -7.06 (-1.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Denali Therapeutics Stock Gets Technical Rating Upgrade ↗
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today ↗
 
Via Benzinga
News headline image
3 Biotech Stocks to Buy Now: Q3 Edition ↗
Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry. 
Via InvestorPlace
News headline image
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
Unveiling 6 Analyst Insights On United Therapeutics ↗
 
Via Benzinga
News headline image
3 Undervalued Stocks on Track to Double (or More) by 2028 ↗
The stock market is on the brink of a multi-year bull market. Consider these undervalued growth stocks to buy that can double or more by 2028. 
Via InvestorPlace
News headline image
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
Expert Ratings For United Therapeutics ↗
 
Via Benzinga
News headline image
Members of Congress Buy and Sell Stocks. These ETFs Let You Invest Like Democrats or Republicans. ↗
Whether you'd like to invest like Nancy Pelosi or Ted Cruz, you can. But maybe you shouldn't. 
Via The Motley Fool
Topics ETFs
News headline image
7 Undervalued Biotech Stocks to Buy for Big-Time Returns ↗
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. 
Via InvestorPlace
News headline image
Chart Of The Day: United Therapeutics - Drugs For Chronic Illnesses ↗
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening... 
Via Talk Markets
News headline image
UroGen Pharma Stock Earns 91 RS Rating ↗
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
News headline image
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
When you look at NASDAQ:UTHR, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Arcellx Stock Earns Relative Strength Rating Upgrade ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
News headline image
The 3 Best Medical Device Stocks to Buy in June 2024 ↗
Medical devices are at the forefront of the digitalization of medicine. making these the three best medical device stocks to buy. 
Via InvestorPlace
News headline image
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
News headline image
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
News headline image
Krystal Biotech Stock Sees RS Rating Jump To 91 ↗
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Halozyme Therapeutics Scores RS Rating Jump To 91 ↗
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. 
Via Investor's Business Daily
News headline image
For those who appreciate value investing, NASDAQ:UTHR is a compelling option with its solid fundamentals. ↗
Investors should take notice ofUNITED THERAPEUTICS CORP (NASDAQ:UTHR)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024 ↗
Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks. 
Via InvestorPlace
News headline image
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics ↗
Liquidia stock retook its 50-day line Monday on a U.S. judge's ruling on a patent dispute with fellow biotech company United Therapeutics. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio ↗
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
News headline image
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating ↗
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
News headline image
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR), an undervalued stock with good fundamentals. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.